BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
    • Interviews
  • News
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Exosomes
  • CAR-T
  • Cord Blood
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » press release

Generex Biotechnology Announces First-in-Human Clinical Trial of the ALTuCELL Cellular Therapy Product Altsulin® (Microencapsulated Sertoli Cells)

November 8, 2019 By Cade Hildreth (CEO) Leave a Comment

Generex Biotechnology
  • Principal investigator Dr. Jaime Guevara Aguirre, world-renowned expert on growth hormone to conduct the trial of Altsulin® (Microencapsulated Sertoli Cells) in Laron Syndrome Patients

  • Laron Syndrome (aka Laron-type dwarfism) is a rare pediatric orphan disease eligible for the FDA “Golden Ticket”

  • Phase IIa proof-of-concept trial paves the way to commercial development of Sertoli Cells for the treatment of Type I Diabetes

[Read more…]

Filed Under: Press Releases Tagged With: press release

Israel Continues to Cultivate Stem Cell Innovation as Cellect and Accellta Enter Into Collaborative Agreement

April 19, 2016 By Cade Hildreth (CEO) Leave a Comment

Israel Continues to Cultivate Stem Cell Innovation as Cellect and Accellta Enter Into Collaborative Agreement

In major news today, Cellect Biomed Ltd. and Accellta announced that they have signed an agreement to evaluate Cellect’s apoptotic induction based technology in combination with Accellta’s stem cell culturing technologies. Cellect Biomed Ltd. is headquartered in Tel Aviv, while Accellta is headquartered in Haifa, Israel.

Accellta is a fascinating stem cell company that can quickly, efficiently, and cost-effectively grow massive quantities of clinical grade cells in xeno-free, feeder-free culture, by utilizing methods of growing the cells in suspension. Specifically, the company can increase a cell population from 1 million cells to 10 billion cells in two weeks with a bi-weekly change of media and an overall cost of about $3,000, by using bioreactors to do it in a very efficient way. Using traditional adherent culture, this would take about 70 liters of medium and an overall cost of $150,000, because it would take 40 to 50 days to do the expansion. [Read more…]

Filed Under: Press Releases, Stem Cells Tagged With: Accellta, Cellect, press release, stem cells

STEMCELL Technologies Partners with IMBA to Commercialize Brain Organoids
(‘Mini Brains’) for Researchers

April 15, 2016 By Cade Hildreth (CEO) Leave a Comment

STEMCELL Technologies Partners with IMBA to Commercialize Brain Organoids for Researchers

In major news released today, STEMCELL Technologies announced that it has partnered with the Institute of Molecular Biotechnology (IMBA) in Vienna, Austria, to develop products for cerebral organoid culture for researchers worldwide.

Founded in 1993 and headquartered in Vancouver, Canada, STEMCELL Technologies is a diversified provider of stem cell research products. The company is known for utilizing strategic alliances to grow its dominance within the stem cell field. Current partnerships of STEMCELL Technologies include a licensing deal with the Wisconsin Alumni Research Foundation (WARF), iPS Academia Japan Inc., Salk Institute for Biological Sciences, and more.

To learn more, read the full press release released by STEMCELL Technologies, printed with permission from Sam Lloyd-Burton, Senior Product Marketing Manager, Neural and Pluripotent Stem Cell Biology, at STEMCELL Technologies.

[Read more…]

Filed Under: iPS Cells, Neural Stem Cells, Stem Cells Tagged With: iPSCs, neural stem cells, press release, STEMCELL Technologies

Major Announcements in Stem Cell Sector – Cynata, Gamida Cell, Pluristem, Universal Cells, and More

April 14, 2016 By Cade Hildreth (CEO) Leave a Comment

Major Announcements in Stem Cell Sector - Cynata, Gamida Cell, Pluristem, Universal Cells, and More

Suffice it to say, it has been a banner week in the world of stem cells. In this rapidly-changing market environment, it can be difficult to keep up with current events. To help you out, we’ve released new content on stem cell markets that we are excited to share with you. Let me know what you think! [Read more…]

Filed Under: Cord Blood, iPS Cells, Stem Cells Tagged With: cynata therapeutics, gamida cell, Pluristem, press release, Universal Cells

Breaking: Cynata Reports Extremely Positive Interim Data for MSC Product, CYP-001, in Model of GvHD

April 7, 2016 By Cade Hildreth (CEO) Leave a Comment

Breaking: Cynata Reports Extremely Positive Interim Data for MSC Product, CYP-001, in Model of GvHD

Australian stem cell company Cynata Therapeutics released news today than interim analysis clearly demonstrates efficacy of Cynata’s unique Cymerus™ mesenchymal stem cell (MSC) product, CYP-001, in a preclinical model of Graft-versus-Host disease (GvHD).  This disease often follows a bone marrow transplant procedure and occurs when the immune cells in the donor material (the graft) attack the recipient’s tissues (the host) as “foreign”.  Bone marrow transplants are used in the treatment of certain cancers, including leukaemia. [Read more…]

Filed Under: Stem Cells Tagged With: cynata therapeutics, manufacturing, mesenchymal stem cells, press release

  • 1
  • 2
  • 3
  • …
  • 8
  • Next Page »

Nanocellect

Marathon Products

Let’s Get Social

  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest
  • Instagram
Menu
  • Blog
  • Stem Cell News
    • Press Releases
  • Stem Cells
    • HSCs
    • iPS Cells
    • MSCs
    • Neural Stem Cells
    • Adipose SCs
  • Exosomes
  • Cell Therapy
    • CAR-T
  • Cord Blood
  • Interviews

Cart

Top Rated Products

  • Job Posting on BioInformant Job Posting on BioInformant.com - Your Perfect Hire Is In Our Audience
    Rated 0 out of 5
    $297
  • U.S. Cord Blood Banking Survey Cord Blood Banking Survey of U.S. Parents [2017]
    Rated 0 out of 5
    $197
  • Exosome Companies 2020 Global Database of Exosome Companies
    Rated 0 out of 5
    $149 $97
My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2022 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: Info@BioInformant.com | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.